Mutation of as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with Mutation.

Mesenchymal-epithelial transition () gene has been identified as a promising target for treatments. However, different sites of the mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of as a possible mechanism of acquired resistance to crizotinib in a patient with mutation during disease progression.